if you look at the ackman presentation, the media has gottan VRX all wrong. the strategy the depends on price hikes is not a sigificant part of the business. going forward the company is not even planning to use that much more. furthermore, the stock, at $93, is a buy even with no growth. it trades at 6-7 times cashflows. and health care cash flows tend to be more durable than other stuff. They are also planning to use their cashflows to delever the balance sheet and turn themselves into investment grade
The best trades I've done have been buying when everyone has been selling, but the trick is to not be too hasty, and to scale in because we really can't tell where the bottom will be.
Do you have a view of how much lower this might go? Citron has been talking $50, but a lot of that hinged on Philidor and I've seen news that Valeant has cut business ties with Philidor.
I really haven't paid any attention to this, so I'm thinking what is the base line business value we should be looking at as a trigger to buy?